WALTHAM, Mass.--(BUSINESS WIRE)-- (NYSE: RVTY), announced today that its business has launched the (CE-IVDR), an automated indirect immunofluorescence test (IIFT) system for autoimmune disease diagnostics. Now available in countries accepting the CE mark, this all-in-one solution increases the efficiency of the entire IIFT process, encompassing sample preparation, incubation, washing and mounting of slides as well as image acquisition and analysis. “Traditional IIFT processing can be tedious and time-consuming, requiring the expertise of specially trained lab technicians and a dark room,”...
Moody's Investors Service said PerkinElmer, Inc.'s announcement that it will divest its Applied, Food and Enterprise Services businesses to private equity firm New Mountain Capital, for a total consideration of $2.45 billion in cash, has no impact on the company's Baa3 senior unsecured rating and st...
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
The independent financial analyst theScreener just requalified the general evaluation of PERKINELMER (US), active in the Medical Equipment industry. As regards its fundamental valuation, the title still shows 1 out of 4 stars and its market behaviour is seen as moderately risky. theScreener believes that the unfavourable environment weighs on the sector and penalises the company, which sees a downgrade to its general evaluation to Slightly Negative. As of the analysis date January 14, 2022, the ...
WALTHAM, Mass.--(BUSINESS WIRE)-- (NYSE: PKI), a global leader innovating for a healthier world, today released its 2021 Corporate Social Responsibility (CSR) Report, which summarizes the latest achievements of its environmental, social and governance (ESG) program. The report titled, “,” also outlines four new ESG commitments unveiled by the Company earlier this year and describes its reporting framework established in accordance with guidelines from The Sustainability Accounting Standards Board (SASB). PerkinElmer’s 2021 CSR Report is organized by the three pillars of its ESG strategy – Go...
WALTHAM, Mass.--(BUSINESS WIRE)-- (NYSE: PKI) announced today that the U.S. Food and Drug Administration (FDA) has issued Emergency Use Authorization (EUA) for the assay. Qualified laboratories can immediately begin using this single test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs and mid-turbinate swabs. COVID-19, flu and RSV infections are highly contagious and often cannot be differentiated based on symptoms alone. The U.S. Centers for...
Rating Action: Moody's assigns Baa3 rating to PerkinElmer's notes offering. Global Credit Research- 08 Sep 2021. New York, September 08, 2021-- Moody's Investors Service assigned a Baa3 rating to the proposed offering of $2.3 billion senior unsecured multi-tranche notes of PerkinElmer, Inc..
Full Article at IIR has reaffirmed its Recommended rating for PIA after undertaking a review post the appointment of a new Portfolio Manager, Harding Loevner. The full report can be found on the IIR website. On 26 July 2021, Pengana International Equities Limited (PIA) announced a fully franked dividend of 1.35 cents per share for the June quarter. This represents an 8% increase on the March quarter dividend and takes the total dividends declared for FY21 of 5.1 cents per share, fully franked....
Rating Action: Moody's affirms PerkinElmer's Baa3 senior unsecured rating; outlook changed to stable. Global Credit Research- 26 Jul 2021. New York, July 26, 2021-- Moody's Investors Service affirmed PerkinElmer, Inc.' s Baa3 senior unsecured rating following the announcement of the $5.3 billion acquisition of BioLegend.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.